Houston, TX, (March 23, 2005) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) announced today that a manuscript reporting the results of studies conducted by Dr. Yin Chen, Vice President of R & D and Dr. Xin-Xing Tan, Senior Scientist was accepted for publication in the respected scientific journal Biochemistry. This paper reports the successful use of the company's proprietary cell-based DNA screening and targeting method to discover novel antibacterial compounds and potential drug-susceptible molecular targets.
Drs. Chen and Tan's paper titled, "A Novel Genomic Approach Identifies Bacterial DNA-Dependent RNA Polymerase as the Target of an Antibacterial Oligodeoxynucleotide, RBL1" will be published in an upcoming issue of the American Chemical Society's, journal Biochemistry. "The purpose of Biochemistry is to publish the results of original research that contribute significantly to the understanding of the mechanism of biological phenomena in terms of molecular structure and/or function. Biochemistry investigates the rapidly changing arena where chemistry, biochemistry and molecular and cell biology interrelate."
Dr. Malcolm Skolnick, Chairman/CEO, stated. "Our peers in the international medical research community continue to recognize and validate our scientific advances. This latest publication in this prestigious journal represents an important step in the application of our technology to the treatment of disease. Application of genetic techniques in disease control is the future of medicine and our mission at CytoGenix is to bring this technology from the laboratory to the clinic".
"Following the success of our compounds against Escherichia Coli to prevent sepsis in animal experiments, this discovery is the basis for development of antibacterial compounds targeting highly antibiotic-resistant strains of Staphylococcus and Streptococcus bacteria", adds Dr. Skolnick.
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 48 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: CytoGenix, Inc., Communications Director - Juan Ferreira, (407) 774-9949
